Over the last 7 days, the United States market has risen by 2.9%, and over the past year, it is up 12%, reflecting a period of growth and optimism. In such a climate, identifying stocks with solid financials and growth potential becomes crucial for investors seeking value. While penny stocks may seem like a term from another era, they continue to represent opportunities in smaller or emerging companies that can offer both affordability and potential upside when chosen wisely.
Top 10 Penny Stocks In The United States
NameShare PriceMarket CapRewards & RisksSafe Bulkers (NYSE:SB)$3.75$393.17M✅ 4 ⚠️ 3 Tuya (NYSE:TUYA)$2.73$1.64B✅ 3 ⚠️ 3 Perfect (NYSE:PERF)$1.78$181.29M✅ 3 ⚠️ 0 Flexible Solutions International (NYSEAM:FSI)$4.40$55.65M✅ 1 ⚠️ 2 Imperial Petroleum (NasdaqCM:IMPP)$2.51$86.38M✅ 3 ⚠️ 2 Table Trac (OTCPK:TBTC)$4.7025$21.82M✅ 2 ⚠️ 2 BAB (OTCPK:BABB)$0.7913$5.75M✅ 2 ⚠️ 3 Lifetime Brands (NasdaqGS:LCUT)$3.28$73.52M✅ 3 ⚠️ 2 New Horizon Aircraft (NasdaqCM:HOVR)$0.6822$21.41M✅ 3 ⚠️ 5 CBAK Energy Technology (NasdaqCM:CBAT)$0.872$78.43M✅ 4 ⚠️ 1
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: The Oncology Institute, Inc. is a U.S.-based company offering a range of medical oncology services with a market cap of $226.50 million.
Operations: Revenue Segments: No specific revenue segments are reported for this U.S.-based company providing medical oncology services.
Market Cap: $226.5M
The Oncology Institute, Inc. is navigating the challenges typical of penny stocks, with high volatility and significant debt levels—a net debt to equity ratio of 673.8%. Despite being unprofitable and not expected to achieve profitability in the next three years, its revenue is projected to grow by 15.87% annually. Recent developments include reaffirmed revenue guidance for 2025 between US$460 million and US$480 million, strategic partnerships enhancing clinical research access, and a shelf registration filing for US$76.79 million in common stock offerings. The company has also launched initiatives like the Florida Oncology Network to expand its care footprint.
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Ardelyx, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing medicines for unmet medical needs globally, with a market cap of approximately $928.31 million.
Operations: The company generates revenue primarily from the development and commercialization of biopharmaceutical products, amounting to $361.71 million.
Market Cap: $928.31M
Ardelyx, Inc. is experiencing the volatility typical of penny stocks, with a focus on developing innovative treatments like IBSRELA and XPHOZAH. Despite being currently unprofitable with a negative return on equity of -36.91%, the company has shown promising revenue growth, reporting US$74.11 million in Q1 2025 compared to US$46.02 million a year ago. Ardelyx's short-term assets significantly exceed its liabilities, providing some financial stability amidst high debt levels that have increased over five years. Recent board appointments and product announcements highlight strategic efforts to strengthen its market position in biopharmaceuticals for unmet medical needs.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Clover Health Investments, Corp. offers Medicare Advantage plans in the United States and has a market cap of approximately $1.80 billion.
Operations: The company generates revenue primarily through its Insurance segment, which accounted for $1.49 billion.
Market Cap: $1.8B
Clover Health Investments is navigating the penny stock landscape with a focus on Medicare Advantage plans, reporting a reduced net loss of US$1.27 million in Q1 2025 from US$19.17 million a year ago. Despite being unprofitable and having a negative return on equity, it remains debt-free and its short-term assets cover both short- and long-term liabilities, providing some financial cushion. Recent leadership changes include the appointment of Dr. Shelly Gupta as Chief Medical Officer to enhance clinical operations and patient access initiatives, while significant insider selling may raise concerns among investors about internal confidence levels.
Taking Advantage
Reveal the 723 hidden gems among our screener with a single click here.
Curious About Other Options?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Leave a Reply